Increasing evidence indicates that dysfunctions within the cGAS-STING signaling potentially mediate the pathogenesis of diverse digestive diseases, such as inflammatory bowel disease (IBD), non-alcoholic fatty liver disease (NAFLD), and colorectal cancer (CRC) (13–16). Here, STING1 is linked to metabolic dysfunction-associated steatotic liver disease.